콘텐츠로 건너뛰기
Merck
모든 사진(1)

주요 문서

모든 문서 보기

Q0632

Sigma-Aldrich

Quinapril hydrochloride

≥98% (HPLC), solid

동의어(들):

(3S)-2-[(2S)-2-[[(1S)-1-(Ethoxycarbonyl)-3-phenylpropyl]amino]-1-oxopropyl]-1,2,3,4-tetrahydro-3-isoquinolinecarboxylic acid hydrochloride

로그인조직 및 계약 가격 보기
모든 사진(1)

About This Item

실험식(Hill 표기법):
C25H30N2O5 · HCl
CAS Number:
82586-55-8
Molecular Weight:
474.98
MDL number:
MFCD00889215
UNSPSC 코드:
41116107
PubChem Substance ID:
329823858
NACRES:
NA.77

Quality Level

100

분석

≥98% (HPLC)

형태

solid

색상

white

solubility

H2O: >10 mg/mL

저장 온도

2-8°C

SMILES string

Cl.CCOC(=O)[C@H](CCc1ccccc1)N[C@@H](C)C(=O)N2Cc3ccccc3C[C@H]2C(O)=O

InChI

1S/C25H30N2O5.ClH/c1-3-32-25(31)21(14-13-18-9-5-4-6-10-18)26-17(2)23(28)27-16-20-12-8-7-11-19(20)15-22(27)24(29)30;/h4-12,17,21-22,26H,3,13-16H2,1-2H3,(H,29,30);1H/t17-,21-,22-;/m0./s1

InChI key

IBBLRJGOOANPTQ-JKVLGAQCSA-N

유전자 정보

human ... ACE(1636)

유사한 제품을 찾으십니까? 방문 제품 비교 안내

애플리케이션

Quinapril hydrochloride has been used as an angiotensin-converting enzyme (ACE) inhibitor to study its effects on renal tubular epithelial cell proliferation in human renal tubular epithelial cells. It has also been used as an ACE inhibitor to evaluate its effects on the expression of angiotensin II (AII) in patient-derived Atheroma samples.

생화학적/생리학적 작용

Quinapril has been studied to exhibit therapeutic effects against hypertension and congestive heart failure.
Quinapril is a short-acting angiotensin converting enzyme (ACE) inhibitor.

픽토그램

Health hazard
GHS08

신호어

Danger

유해 및 위험 성명서

H361d,H372

Hazard Classifications

Repr. 2 - STOT RE 1

Storage Class Code

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

WGK

WGK 3

Flash Point (°F)

Not applicable

Flash Point (°C)

Not applicable

개인 보호 장비

Eyeshields, Gloves, type N95 (US)

시험 성적서(COA)

제품의 로트/배치 번호를 입력하여 시험 성적서(COA)을 검색하십시오. 로트 및 배치 번호는 제품 라벨에 있는 ‘로트’ 또는 ‘배치’라는 용어 뒤에서 찾을 수 있습니다.

이 제품을 이미 가지고 계십니까?

문서 라이브러리에서 최근에 구매한 제품에 대한 문서를 찾아보세요.

문서 라이브러리 방문

D Lyons et al.
European journal of clinical pharmacology, 51(5), 373-378 (1997-01-01)
Different ACE inhibitors can be distinguished in vitro by their affinity for converting enzyme in vascular and other tissues. Quinapril appears to be amongst the more effective inhibitors of vascular tissue ACE in vitro. This study assesses the in vivo
Marcel Ruzicka et al.
American journal of hypertension, 23(11), 1179-1182 (2010-07-17)
Angiotensin-converting enzyme (ACE) inhibitors differ in their lipophilic/hydrophilic index that determines their tissue bioavailability and affinity to ACE, which may result in major differences in the degree of blockade of cardiac ACE. We evaluated the hypothesis that in patients with
Tomoe Fujita et al.
The Journal of pharmacology and experimental therapeutics, 341(3), 626-633 (2012-03-06)
Indoxyl sulfate (IS) is an organic anion uremic toxin that accumulates in patients with chronic kidney disease (CKD). The aims of this study were to examine the kinetic profiles of IS in humans at a steady state after multiple doses
Christine R Culy et al.
Drugs, 62(2), 339-385 (2002-01-31)
Quinapril is rapidly de-esterified after absorption to quinaprilat (the active diacid metabolite), a potent angiotensin converting enzyme (ACE) inhibitor. Quinapril produces favourable haemodynamic changes, and improves ventricular and endothelial function in patients with various cardiovascular disorders; these effects are mediated
A M D Watson et al.
Diabetologia, 53(1), 192-203 (2009-10-29)
There is convincing evidence that the endothelin system contributes to diabetic nephropathy and cardiovascular disease. This study aimed to assess the effects of the non-peptidergic endothelin receptor A (ETA) antagonist avosentan in a mouse model of accelerated diabetic nephropathy and
모든 관련된 서류 보기

자사의 과학자팀은 생명 과학, 재료 과학, 화학 합성, 크로마토그래피, 분석 및 기타 많은 영역을 포함한 모든 과학 분야에 경험이 있습니다..

고객지원팀으로 연락바랍니다.